12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PNT2258: Phase I data

Top-line data from Phase I trial in 22 patients showed that 1-150 mg/m 2 doses of PNT2258 were well tolerated, with an MTD of 150 mg/m 2 on days 1-5 of a 21-day cycle. Fatigue was the most common adverse event reported. DLTs included grade 3 increase...

Read the full 214 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >